FINWIRES · TerminalLIVE
FINWIRES

$DGX

12 stories mentioning DGX

Every FINWIRES story that references DGX, newest first.

Insider Trading

Quest Diagnostics Insider Sold Shares Worth $1,941,400, According to a Recent SEC Filing

J. E. Davis, Director, Chief Executive Officer and President, on June 01, 2026, sold 10,000 shares in Quest Diagnostics (DGX) for $1,941,400. Following the Form 4 filing with the SEC, Davis has control over a total of 132,423 common shares of the company, with 132,423 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1022079/000159983726000005/xslF345X05/wk-form4_1780439916.xml

$DGX
Wire

UBS Adjusts Quest Diagnostics Price Target to $220 From $210, Maintains Neutral Rating

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $223.56, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $203.15, Change: $-1.99, Percent Change: -0.97%

$DGX
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Quest Diagnostics

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our 12-month price target at $235. This is based on a forward P/E of 21.9x our 2026 EPS estimate, a premium to DGX's three-year forward average of 16.8x due to our view of strengthening sales and earnings growth, backed by higher health care utilization trends and some regulatory relief due to postponement of lab reimbursement cuts until at least 2027. We think lab testing providers remain a relatively well-positioned area within health care given lower policy risks, supportive testing demand, and attractive earnings growth potential. On a compounded annual basis from 2025-2028, we expect near 8% EPS growth, raising our 2026 EPS to $10.73 from $10.60 and 2027 EPS to $11.50 from $11.42. We also anticipate additional smaller M&A opportunities, along with healthy dividend increases (recent 7.5% boost; shares yield 1.7%) as cash flow generation remains supportive over the near term.

$DGX
Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.9%.The iShares Biotechnology ETF (IBB) decreased 1%.In corporate news, Passage Bio (PASG) faces a tougher path after US regulators told the company it will need to run a randomized study to support approval of its experimental treatment PBFT02, a move that adds time, cost, and uncertainty, Wedbush said Tuesday in a report. Wedbush downgraded Passage Bio's stock to neutral from outperform and cut its price target to $8 from $32. Passage Bio shares dropped 2.9%.Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.7%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 7%.Quest Diagnostics (DGX) shares popped more than 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.

$DGX$MRK$PASG$UNH
Wire

Evercore ISI Adjusts Danaher Price Target to $225 From $210, Maintains Outperform Rating

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $203.42, Change: $+7.11, Percent Change: +3.62%

$DGX
Sectors

Sector Update: Health Care Stocks Softer Tuesday Afternoon

Health care stocks declined Tuesday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.7%.In corporate news, Merck (MRK) and Japanese health care company Eisai said Tuesday that phase 3 trials of two drug combinations failed to meet primary endpoints of progression-free survival and overall survival as a first-line treatment of patients with advanced clear cell renal cell carcinoma compared with Keytruda plus Lenvima. Merck shares fell 3.9%.UnitedHealth Group (UNH) raised its full-year earnings outlook on Tuesday as the health insurance giant recorded an unexpected annual increase in its first-quarter results. Its shares jumped past 8%.Quest Diagnostics (DGX) shares popped 4% after it reported higher Q1 adjusted earnings and net revenue and raised its 2026 outlook.

$DGX$MRK$UNH
Wire

Jefferies Raises Quest Diagnostics Price Target to $225 From $220

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $204.33, Change: $+8.02, Percent Change: +4.09%

$DGX
Wire

Leerink Partners Adjusts Price Target on Quest Diagnostics to $240 From $235, Maintains Outperform Rating

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $219, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $205.41, Change: $+9.10, Percent Change: +4.64%

$DGX
Sectors

Sector Update: Health Care Stocks Flat to Higher Premarket Tuesday

Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.8%.UnitedHealth Group (UNH) stock was up more than 8% after the company reported higher Q1 adjusted earnings and revenue, and increased its 2026 adjusted EPS guidance.Quest Diagnostics (DGX) stock was up more than 3% after the company reported higher Q1 adjusted earnings and net revenue, and raised its 2026 outlook.Danaher (DHR) shares were up 0.8% after the company posted higher Q1 adjusted earnings and sales, and lifted its 2026 adjusted diluted EPS outlook.

$DGX$DHR$IBB$UNH$XLV
Research

Research Alert: Dgx: Testing Volume Growth Drives Q1 Sales, Earnings Beats; Raises 2026 Outlook

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Quest Diagnostics (DGX) delivered strong Q1 results with revenue of $2.895B, up 9.2% Y/Y, as robust requisition volume grew 10.9% (+10.8% organic) across its physician, hospital, and consumer segments. Diagnostic Information Services sales rose 9.4% while the adjusted operating margin improved modestly to 15.4% from 15.3% in the prior year. The company demonstrated progress in Advanced Diagnostics with strong demand for AD-Detect Alzheimer's blood tests and launched its AI Companion tool with 350,000 patient engagements since rollout. Management raised 2026 guidance, with the sales growth midpoint rising 0.7% to $11.84B and the adjusted EPS midpoint increasing 1.2% to $10.73, reflecting 7.3% and 8.9% growth, respectively, versus 2025. We await further details on DGX's progress in dialysis lab and water-purity testing services, as well as updates on its questhealth.com consumer channel development in the upcoming earnings call. Shares traded up approximately 3% in premarket action following the strong results.

$DGX
Wire

Quest Diagnostics Says City of Hope Evaluating Haystack MRD Test in Multiple Cancers

Quest Diagnostics (DGX) said Thursday that City of Hope is evaluating the Haystack MRD circulating tumor DNA test in a research program to help improve disease management for patients with solid tumor cancers.The company said 14 City of Hope sites across the US are participating in the study, which is expected to enroll around 500 patients with breast, colorectal, ovarian, and prostate cancers.The program will evaluate Haystack MRD in detecting minimal residual disease, monitoring treatment response, and identifying recurrence ahead of standard imaging under neoadjuvant, adjuvant, and post-treatment settings, Quest Diagnostics said.Shares of Quest Diagnostics were up 1% in Thursday trading.Price: $193.42, Change: $+2.00, Percent Change: +1.04%

$DGX
Wire

Baird Adjusts Price Target on Quest Diagnostics to $224 From $219, Maintains Neutral Rating

Quest Diagnostics (DGX) has an average rating of overweight and mean price target of $218.69, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $192.51, Change: $-0.36, Percent Change: -0.19%

$DGX
DGX News | FINWIRES